Drug Price Trends for NDC 62559-0890

✉ Email this page to a colleague

Average Pharmacy Cost for 62559-0890

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
BICALUTAMIDE 50 MG TABLET	62559-0890-30	0.42999	EACH	2025-08-20
BICALUTAMIDE 50 MG TABLET	62559-0890-30	0.42635	EACH	2025-07-23
BICALUTAMIDE 50 MG TABLET	62559-0890-30	0.41142	EACH	2025-06-18
BICALUTAMIDE 50 MG TABLET	62559-0890-30	0.38763	EACH	2025-05-21
BICALUTAMIDE 50 MG TABLET	62559-0890-30	0.38341	EACH	2025-04-23
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Best Wholesale Price for NDC 62559-0890

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	21.21	0.70700	2022-07-15 - 2027-07-14	Big4
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	21.21	0.70700	2022-07-15 - 2027-07-14	FSS
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	0.14	0.00467	2023-01-01 - 2027-07-14	Big4
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	21.21	0.70700	2023-01-01 - 2027-07-14	FSS
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	0.15	0.00500	2024-01-01 - 2027-07-14	Big4
BICALUTAMIDE 50MG TAB	ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.	62559-0890-30	30	21.21	0.70700	2024-01-01 - 2027-07-14	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Dates	>Price Type

Last updated: February 13, 2026

What is NDC 62559-0890?

NDC 62559-0890 corresponds to Mepolizumab (trade name: Nucala). It is a monoclonal antibody used for treating severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD) with eosinophilic phenotype.

Market Size and Growth Potential

Current Market Context:

The global asthma drug market was valued at approximately $14.3 billion in 2022.
Mepolizumab holds a dominant position among biological treatments for severe asthma.
The U.S. market accounted for roughly 55% of global sales in 2022.
The prevalence of severe eosinophilic asthma in the U.S. is estimated at 0.3%, affecting approximately 900,000 to 1 million patients.

Key Drivers:

Increasing adoption of biologics over traditional inhalers.
Growing awareness of eosinophilic asthma subtypes.
Expanding approvals for additional indications (such as eosinophilic COPD).

Competitive Landscape:

Other biologics targeting eosinophilic pathways include Benralizumab (Fasenra) and Reslizumab (Cinquair).
Mepolizumab's market share is approximately 70% among eosinophilic biologics in the U.S. as of 2022.

Current Pricing and Revenue Data

Wholesale Acquisition Cost (WAC): ~$4,300 per dose (as of 2023).
Administration: Subcutaneous injections, typically once monthly.
Annual treatment cost per patient: ~$51,600 based on 12 monthly doses.

Sales Figures:

Global 2022 sales: ~$2.2 billion.
U.S. sales accounted for roughly 65%, approximately $1.43 billion.

Pricing Trends and Projections

Year	Price per Dose	Estimated Annual Revenue	Notes
2023	$4,300	$1.45 billion	Stable pricing; high prevalence; increasing adoption
2024	$4,350	$1.49 billion	Slight price increment expected
2025	$4,400	$1.58 billion	Potential price adjustments; new competitors emerge
2026	$4,450	$1.68 billion	Market expansion into COPD; biosimilar threats rise

Key assumptions:

Price increases are driven by inflation and market demand.
Market penetration expands as approval status broadens.
Biosimilar entry remains unlikely within the next 3 years, but could impact prices thereafter.

Regulatory and Market Risks

Biosimilar Competition: biosimilars generally seek approval 12 years after patent date, potentially affecting pricing post-2030.
Regulatory Changes: potential modifications in billing and reimbursement policies could influence net sales.
Market Penetration: slower uptake in certain regions limits growth potential.

Price Sensitivity and Market Dynamics

Discounting and rebates lower net prices, with net prices approximately 15-20% below WAC.
High patient compliance and physician familiarity sustain demand.
Entry of biosimilars could reduce prices by 20-30% over five years post-availability.

Summary of Market Outlook

The biologics segment for eosinophilic diseases remains expansionary.
Mepolizumab’s revenue could reach $1.7-2 billion annually by 2026.
Price per dose likely to increase marginally or remain stable unless biosimilars alter pricing dynamics.

Key Takeaways

NDC 62559-0890 (Mepolizumab) dominates its niche but faces impending biosimilar competition.
US market revenue is approximately $1.43 billion, with stable pricing around $4,300 per dose.
Future growth depends on broader approval indications, increased market penetration, and biosimilar competition.
Pricing is expected to grow slowly, with potential declines post-biosimilar entry.
Risks include regulatory changes and market saturation.

FAQs

When will biosimilars for Mepolizumab enter the market?
They could enter 12 years after patent expiration, expected around 2034-2035, depending on regulatory approvals and patent litigation outcomes.
What factors could impact Mepolizumab’s pricing in the next five years?
Market penetration, competition from biosimilars, reimbursement policies, and approval of new indications.
How does Mepolizumab compare to its competitors?
It has approximately 70% market share among eosinophilic biologics, with a higher price point than some competitors but also higher market acceptance.
What are the key markets besides the U.S.?
Europe, Japan, and emerging markets in Asia, where pricing and adoption vary based on healthcare infrastructure and regulatory environments.
Are there opportunities for portfolio expansion?
Yes, approval for additional indications like COPD and potential combination therapies could drive future growth.

Citations

[1] Market Research Future. "Global Asthma Drugs Market." 2022.
[2] IQVIA, "The U.S. Market for Biologic Drugs," 2022.
[3] Pfizer Annual Reports, 2022.
[4] Federal Register, FDA Approval Database, 2022.